Phase I/II trial of Weekly Bortezomib with Lenalidomide and Dexamethasone in First Relapse or Primary Refractory Myeloma


Disclosures: M.J.K.: received research support from Celgene; attended advisory boards for Celgene and Janssen Pharmaceuticals. P.S. received research support from Celgene, Janssen, Millennium, Onyx. Received honoraria from Celgene, Janssen, Millennium, Onyx. E. V. received research support from Janssen. G.B. received research support from Celgene. H.L. attended advisory boards for Celgene and Janssen. A.B. attended advisory boards for Celgene and Amgen. W.G.A., M-D.L., O.W., E.M., S. W., B.T., P.C., M.S., P.W. have no disclosures.

Contributions: Authorship Contribution: P.S. was the principal investigator; P.S., H. L., E.V. designed the research; all authors provided study materials or patients/ performed the research; W.G.A. performed statistical analyses; W.G.A., A.B, P.S. analyzed and interpreted the data; W.G.A., A.B., P.S. wrote the manuscript; and all authors reviewed the draft manuscript and approved the final version for submission.